slc17a8

slc17a8

Introduction

SLC17A8 (Solute Carrier Family 17 Member A8) encodes vesicular glutamate transporter 3 (VGLUT3), also known as VGLUT3 or SLC17A8. Unlike other VGLUTs (VGLUT1/SLC17A7 and VGLUT2/SLC17A6) that are expressed primarily in glutamatergic neurons, VGLUT3 has a unique expression pattern in monoaminergic and cholinergic neurons, where it packages glutamate as a cotransmitter alongside dopamine, serotonin, or acetylcholine. This glutamatergic cotransmission plays critical roles in modulating synaptic signaling and has important implications for neurodegenerative diseases, particularly Parkinson's disease. SLC17A8 mutations cause both autosomal dominant hearing loss (DFNA25) and recessive auditory neuropathy, highlighting its essential role in auditory system function.

slc17a8

Introduction

SLC17A8 (Solute Carrier Family 17 Member A8) encodes vesicular glutamate transporter 3 (VGLUT3), also known as VGLUT3 or SLC17A8. Unlike other VGLUTs (VGLUT1/SLC17A7 and VGLUT2/SLC17A6) that are expressed primarily in glutamatergic neurons, VGLUT3 has a unique expression pattern in monoaminergic and cholinergic neurons, where it packages glutamate as a cotransmitter alongside dopamine, serotonin, or acetylcholine. This glutamatergic cotransmission plays critical roles in modulating synaptic signaling and has important implications for neurodegenerative diseases, particularly Parkinson's disease. SLC17A8 mutations cause both autosomal dominant hearing loss (DFNA25) and recessive auditory neuropathy, highlighting its essential role in auditory system function.

<div class="infobox infobox-gene">
<div class="infobox-header">SLC17A8</div>
<div class="infobox-row"><span class="infobox-label">Gene Symbol</span><span class="infobox-value">SLC17A8</span></div>
<div class="infobox-row"><span class="infobox-label">Full Name</span><span class="infobox-value">Solute Carrier Family 17 Member A8 (VGLUT3)</span></div>
<div class="infobox-row"><span class="infobox-label">Chromosomal Location</span><span class="infobox-value">12q23.1</span></div>
<div class="infobox-row"><span class="infobox-label">NCBI Gene ID</span><span class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/246213" target="_blank">246213</a></span></div>
<div class="infobox-row"><span class="infobox-label">OMIM</span><span class="infobox-value"><a href="https://www.omim.org/entry/607557" target="_blank">607557</a></span></div>
<div class="infobox-row"><span class="infobox-label">Ensembl ID</span><span class="infobox-value"><a href="https://ensembl.org/Homo_sapiens/ENSG00000179520" target="_blank">ENSG00000179520</a></span></div>
<div class="infobox-row"><span class="infobox-label">UniProt ID</span><span class="infobox-value"><a href="https://www.uniprot.org/uniprot/Q9NY26" target="_blank">Q9NY26</a></span></div>
<div class="infobox-row"><span class="infobox-label">Associated Diseases</span><span class="infobox-value">[Parkinson's Disease](/diseases/parkinsons-disease), [Hearing Loss](/diseases/hearing-loss), Auditory Neuropathy</span></div>
</div>

Overview

SLC17A8 Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, ion transport, protein homeostasis, and synaptic transmission. VGLUT3 is unique among the three VGLUT family members because of its expression in non-glutamatergic neurons, establishing glutamate as a cotransmitter in dopaminergic, serotonergic, and cholinergic systems. This cotransmission has profound implications for understanding the pathophysiology of Parkinson's disease and other neurodegenerative disorders.

Dysregulation or mutations in this gene contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders. The role of VGLUT3 in excitotoxicity makes it a potential therapeutic target for neuroprotection strategies.

Function

SLC17A8 encodes vesicular glutamate transporter 3 (VGLUT3), responsible for packaging glutamate into synaptic vesicles in neurons. VGLUT3 belongs to the SLC17 family of organic anion transporters, which includes other VGLUTs (VGLUT1 and VGLUT2) as well as vesicular nucleotide transporters and sialic acid transporters. The transport mechanism relies on the proton gradient established by V-ATPase, which drives glutamate uptake into synaptic vesicles against concentration gradients.

Glutamate Cotransmission

Unlike other VGLUTs (VGLUT1 and VGLUT2), VGLUT3 is expressed in neurons that are not primarily glutamatergic, leading to its role as a "cotransmitter" system. This was a paradigm-shifting discovery in neurobiology, as it established that classic monoamine and cholinergic neurons also release glutamate as a signaling molecule. Key aspects include:

• Dopaminergic Cotransmission: VGLUT3 is expressed in a subset of dopaminergic neurons in the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA). These neurons release glutamate alongside dopamine, providing a previously unrecognized excitatory component to dopaminergic signaling. This cotransmission modulates reward learning, motor control, and may contribute to the pathophysiology of Parkinson's disease.
• Serotonergic Cotransmission: In dorsal raphe nucleus neurons, VGLUT3 packages glutamate for corelease with serotonin. This glutamate signaling influences mood, anxiety, and may be relevant to depression and serotonin-related disorders.
• Cholinergic Cotransmission: Basal forebrain cholinergic neurons express VGLUT3 and release glutamate alongside acetylcholine. This glutamatergic component contributes to hippocampal and cortical plasticity, learning, and memory processes.

Mechanistic Insights

VGLUT3 functions through a proton-gradient-dependent transport mechanism. V-ATPase on synaptic vesicle membranes pumps protons into the vesicle lumen, creating an electrochemical gradient. VGLUT3 exchanges external glutamate for internal protons, using this gradient to concentrate glutamate within vesicles at ratios of up to 10,000:1 relative to cytoplasm. This ensures sufficient glutamate for synaptic release and subsequent activation of postsynaptic glutamate receptors.

Disease Associations

Parkinson's Disease

VGLUT3 plays a complex and multifaceted role in PD. While VGLUT2 (SLC17A6) is more abundantly expressed in the substantia nigra, VGLUT3 is expressed in a subset of dopaminergic neurons. Altered VGLUT3 expression may affect dopamine-glutamate cotransmission and contribute to excitotoxicity in PD. Specific mechanisms include:

• Excitotoxicity: Excess glutamate release from VGLUT3-expressing neurons can overactivate NMDA and AMPA receptors on postsynaptic neurons, leading to calcium influx, oxidative stress, and neuronal death. This excitotoxic mechanism is particularly relevant in the substantia nigra, where dopaminergic neurons are inherently vulnerable.
• Dysregulated Dopamine-Glutamate Balance: The cotransmission of dopamine and glutamate from the same vesicles creates a tightly regulated signaling system. In PD, loss of VGLUT3 function may disrupt this balance, affecting both dopaminergic and glutamatergic transmission in basal ganglia circuits.
• LRRK2 Interaction: Evidence suggests interactions between VGLUT3 function and LRRK2 (leucine-rich repeat kinase 2), the most common genetic cause of familial PD. LRRK2 mutations may affect vesicular trafficking and glutamate release dynamics.
• Therapeutic Implications: Targeting VGLUT3-mediated glutamate release represents a potential strategy for developing disease-modifying PD therapies. However, the complex role of VGLUT3 in both motor and non-motor symptoms requires careful consideration.

Hearing Loss (DFNA25)

SLC17A8 mutations cause autosomal dominant progressive hearing loss (DFNA25). The gene is highly expressed in inner hair cells of the cochlea, where it is essential for glutamatergic neurotransmission from hair cells to spiral ganglion neurons. The mechanism involves:

• Inner Hair Cell Synapse: VGLUT3 is required for packaging glutamate into synaptic vesicles at the ribbon synapse of inner hair cells. This glutamate release activates AMPA receptors on spiral ganglion neuron dendrites, converting mechanical vibrations into electrical signals.
• Progressive Degeneration: DFNA25-associated mutations lead to progressive loss of inner hair cell function, likely due to impaired synaptic transmission and subsequent spiral ganglion neuron degeneration. Onset typically occurs in adolescence or early adulthood, with progressive hearing loss continuing into middle age.
• Audiometric Profile: Patients with DFNA25 show characteristic high-frequency hearing loss initially, with progressive involvement of lower frequencies. Speech perception is affected relatively early due to the critical role of high-frequency sounds in speech comprehension.

Auditory Neuropathy

Recessive SLC17A8 mutations cause a severe auditory neuropathy phenotype in infants. This condition is characterized by:

• Preserved Outer Hair Cell Function: Unlike typical sensorineural hearing loss, auditory neuropathy shows normal otoacoustic emissions (OAEs) and preserved cochlear microphonic responses, indicating intact outer hair cell function.
• Abnormal Neural Responses: Absent or abnormal auditory brainstem responses (ABRs) indicate disrupted neural transmission from the inner hair cell-synapse to the auditory brainstem.
• Speech Perception Deficits: Despite preserved hair cell function, patients with auditory neuropathy have severe difficulties with speech perception, particularly in noisy environments.
• Molecular Mechanism: Recessive mutations likely result in complete loss of VGLUT3 function, preventing glutamate release from inner hair cells and eliminating the excitatory signal to spiral ganglion neurons.

Potential Alzheimer's Disease Link

While not as well-established as the PD connection, VGLUT3 may play a role in AD through:

• Cholinergic System Dysfunction: VGLUT3 in basal forebrain cholinergic neurons contributes to hippocampal plasticity. Loss of this function may exacerbate cholinergic deficits in AD.
• Excitotoxicity: Dysregulated glutamate signaling from VGLUT3-expressing neurons may contribute to excitotoxic mechanisms in AD.

Expression

VGLUT3 has a unique and distinctive expression pattern that distinguishes it from other VGLUT family members:

Brain Regions

• Substantia nigra pars compacta - subset of dopaminergic neurons (A9 population)
• Ventral tegmental area - subset of dopaminergic neurons (A10 population)
• Dorsal raphe nucleus - subset of serotonergic neurons
• Basal forebrain - cholinergic neurons projecting to hippocampus and cortex
• Lateral hypothalamus - orexin/hypocretin neurons

Peripheral Expression

• Inner hair cells of cochlea - ribbon synapse glutamatergic transmission
• Retina - certain amacrine and bipolar cells
• Pituitary gland - endocrine cell populations
• Enteric nervous system - enteric neurons

Structure and Biochemistry

VGLUT3 is a transmembrane protein with 12 predicted transmembrane domains, consistent with the SLC superfamily structure. The protein contains:

• N-terminal cytoplasmic domain: Contains targeting signals for synaptic vesicle localization
• Transmembrane domains: Form the transport channel for glutamate translocation
• C-terminal cytoplasmic domain: Involved in protein-protein interactions and trafficking

Therapeutic Target Potential

VGLUT3 represents a potential therapeutic target for several conditions:

Parkinson's Disease

• Modulation Strategy: Developing VGLUT3 modulators that reduce excessive glutamate release while preserving dopaminergic function
• Challenge: The bidirectional nature of VGLUT3 function (both protective and detrimental) complicates therapeutic targeting

Hearing Loss

• Gene Therapy: VGLUT3 represents a candidate for gene replacement therapy in recessive auditory neuropathy
• Delivery Challenges: Inner ear delivery and expression in hair cells remain technical hurdles

Neuropsychiatric Disorders

• Depression and Addiction: VGLUT3 in ventral tegmental area and raphe nuclei may represent targets for mood disorders and addiction treatment

Key Publications

See Also

• [Glutamate](/entities/glutamate)
• [VGLUT1 (SLC17A7)](/genes/slc17a7)
• [VGLUT2 (SLC17A6)](/genes/slc17a6)
• [Dopamine](/entities/dopamine)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Auditory System](/mechanisms/cochlear-neurotransmission)

References